[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Becton Dickinson and Company (BDX)

Becton Dickinson and Company (BDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,583,636
  • Shares Outstanding, K 275,540
  • Annual Sales, $ 21,840 M
  • Annual Income, $ 1,678 M
  • EBIT $ 2,002 M
  • EBITDA $ 4,464 M
  • 60-Month Beta 0.19
  • Price/Sales 2.29
  • Price/Cash Flow 7.86
  • Price/Book 2.05

Options Overview Details

View History
  • Implied Volatility 25.97% (+0.23%)
  • Historical Volatility 30.18%
  • IV Percentile 29%
  • IV Rank 34.22%
  • IV High 41.36% on 08/04/26
  • IV Low 17.97% on 08/15/25
  • Expected Move (DTE 7) 5.31 (2.92%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 391
  • Volume Avg (30-Day) 804
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 21,404
  • Open Int (30-Day) 16,819
  • Expected Range 176.66 to 187.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $4.06
  • Number of Estimates 7
  • High Estimate $4.10
  • Low Estimate $4.03
  • Prior Year $3.96
  • Growth Rate Est. (year over year) +2.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
148.34 +22.67%
on 07/14/26
185.32 -1.81%
on 08/13/26
+28.14 (+18.29%)
since 07/13/26
3-Month
140.11 +29.88%
on 06/22/26
185.32 -1.81%
on 08/13/26
+37.79 (+26.21%)
since 05/13/26
52-Week
127.59 +42.62%
on 11/06/25
187.35 -2.87%
on 02/24/26
+27.91 (+18.12%)
since 08/13/25

Most Recent Stories

More News
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery

BDX : 181.97 (-0.88%)
Becton Dickinson: Fiscal Q3 Earnings Snapshot

Becton Dickinson: Fiscal Q3 Earnings Snapshot

BDX : 181.97 (-0.88%)
BD Reports Third Quarter Fiscal 2026 Financial Results

FRANKLIN LAKES, N.J. , Aug. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third...

BDX : 181.97 (-0.88%)
BD's Three Consecutive Quarters of Losses Suggest the Turnaround Timeline Has Shifted

Barchart Research What to Expect from BDX Earnings BDX Generated August 5, 2026 Current Price $170.66 EPS Estimate $$3.14 Consensus Rating Moderate Buy Average Move 5.41% BD's Three Consecutive Quarters...

BDX : 181.97 (-0.88%)
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch

  Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.

BDX : 181.97 (-0.88%)
BD Board Declares Dividend

FRANKLIN LAKES, N.J. , July 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has...

BDX : 181.97 (-0.88%)
Mike Garrison to Retire from BD

FRANKLIN LAKES, N.J. , July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison...

BDX : 181.97 (-0.88%)
Becton, Dickinson and Company Earnings Preview: What to Expect

Becton, Dickinson and Company will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.

XLV : 168.38 (-0.04%)
$SPX : 7,798.99 (+0.65%)
BDX : 181.97 (-0.88%)
WAT : 413.51 (-0.63%)
BD to Announce Financial Results for its Third Quarter of Fiscal 2026

FRANKLIN LAKES, N.J. , July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...

BDX : 181.97 (-0.88%)
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

Recognition from Vizient validates CentroVena One ™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety

BDX : 181.97 (-0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational...

See More

Key Turning Points

3rd Resistance Point 188.30
2nd Resistance Point 186.81
1st Resistance Point 184.39
Last Price 181.97
1st Support Level 180.48
2nd Support Level 178.99
3rd Support Level 176.57

See More

52-Week High 187.35
Last Price 181.97
Fibonacci 61.8% 164.52
Fibonacci 50% 157.47
Fibonacci 38.2% 150.42
52-Week Low 127.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.